Vaxcyte, Inc.(PCVX) Stock Research - Grey Stern Research

Vaxcyte, Inc. (PCVX) Stock Analysis

$70.77 (3.22%)

PCVX Financial Performance


Use the table below to view Vaxcyte, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2024

Metric Value Ranking among Peers
Price $70.77 -
52 Week Low $58.10 -
52 Week High $121.06 -
Market Cap $9.1 Billion 3/17
Gross Margin 0% 13/17
Profit Margin 0% 4/17
EBITDA margin -100% 7/17
Q4 - 2024 Revenue $0 13/17
Q4 - 2024 Earnings -$137.1 Million 17/17
Q4 - 2024 Free Cash Flow -$141.4 Million 16/17
Trailing 4 Quarters Revenue $0 13/17
Trailing 4 Quarters Earnings -$463.9 Million 17/17
Quarterly Earnings Growth 24% 7/17
Annual Earnings Growth -1% 5/17
Quarterly Revenue Growth 0% 8/17
Annual Revenue Growth 0% 9/17
Cash On Hand $387.9 Million 4/17
Short Term Debt $5.9 Million 6/17
Long Term Debt $65.2 Million 8/17

Vaxcyte, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Vaxcyte, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 3/17
PS -1.00 13/17
PB 2.76 12/17
PC 23.49 6/17
Liabilities to Equity 0.06 16/17
ROA -0.13 5/17
ROE -0.14 3/17
Current Ratio 17.09 2/17
Quick Ratio 8.50 5/17
Long Term Debt to Equity 0.02 12/17
Debt to Equity 0.02 13/17
Burn Rate 2.75 4/17
Cash to Cap 0.04 12/17
CCR 1.03 3/17
EV to EBITDA -1.00 5/17
EV to Revenue -1.00 12/17

Company Details

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

CEO: Mr. Grant E. Pickering

Website: https://vaxcyte.com

Address: 353 Hatch Dr Foster City, CALIFORNIA

Exchange: NASDAQ Global Select

Industry: Biotechnology

Vaxcyte, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Vaxcyte, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
BioMarin Pharmaceutical Inc. BMRN $13.9 Billion
Bio-Techne Corporation TECH $9.5 Billion
Syndax Pharmaceuticals, Inc. SNDX $1.2 Billion
Apellis Pharmaceuticals, Inc. APLS $3.0 Billion
Merus N.V. MRUS $3.1 Billion
Liquidia Corporation LQDA $1.3 Billion
Sutro Biopharma, Inc. STRO $62.0 Million
Larimar Therapeutics, Inc. LRMR $153.7 Million
Legend Biotech Corporation LEGN $3.2 Billion
Viridian Therapeutics, Inc. VRDN $1.2 Billion
Travere Therapeutics, Inc. TVTX $1.8 Billion
Nuvalent, Inc. NUVL $5.3 Billion
DICE Therapeutics, Inc. DICE $2.3 Billion
Immunocore Holdings plc IMCR $1.5 Billion
Arcellx, Inc. ACLX $3.8 Billion
Ventyx Biosciences, Inc. VTYX $87.5 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
PCVX Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 0 -$137.1 Million
Q3 2024 $ 0 -$103.1 Million
Q2 2024 $ 0 -$128.7 Million
Q1 2024 $ 0 -$95.0 Million
Q4 2023 $ 0 -$180.8 Million
Q3 2023 $ 0 -$92.7 Million
Q2 2023 $ 0 -$68.3 Million
Q1 2023 $ 0 -$48.4 Million

View All

PCVX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $387.9 Million $3.5 Billion $71.1 Million $3.3 Billion
Q3 2024 $1.1 Billion $3.6 Billion $28.0 Million $3.4 Billion
Q2 2024 $518.7 Million $2.1 Billion $25.6 Million $2.0 Billion
Q1 2024 $611.5 Million $2.1 Billion $27.4 Million $2.0 Billion
Q4 2023 $397.5 Million $1.4 Billion $29.2 Million $1.2 Billion
Q3 2023 $545.1 Million $1.5 Billion $13.8 Million $1.4 Billion
Q2 2023 $531.0 Million $1.5 Billion $15.2 Million $1.4 Billion
Q1 2023 $949.9 Million $1.0 Billion $16.6 Million $944.8 Million

View All

PCVX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2024 -$141.4 Million -$30.0 Million -$662.3 Million
Q3 2024 -$21.7 Million $39.0 Million $532.8 Million
Q2 2024 -$166.8 Million -$45.4 Million -$92.8 Million
Q1 2024 -$171.2 Million -$12.1 Million $214.1 Million
Q4 2023 -$185.9 Million -$57.1 Million -$147.7 Million
Q3 2023 -$64.9 Million -$7.3 Million $14.3 Million
Q2 2023 -$60.6 Million $2.1 Million $150.6 Million
Q1 2023 -$53.3 Million -$5.6 Million -$454.2 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions